Cancer cachexia marker, Growth Differentiation Factor 15 (GDF-15), serum level mapping in real world samples from patients with pancreatic (PANC) or colorectal cancer (CRC)
Category: Presentation
Overview of Tivozanib (Tivo) Safety in Patients with Metastatic Renal Cell Carcinoma (mRCC)
Overview of Tivozanib (Tivo) Safety in Patients with Metastatic Renal Cell Carcinoma (mRCC)
FIERCE-HN: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ficlatuzumab (HGF/c-MET MAb) in Combination with Cetuximab in Participants with Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma (HNSCC)
FIERCE-HN: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ficlatuzumab (HGF/c-MET MAb) in Combination with Cetuximab in Participants with Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma (HNSCC)
Efficacy of second line (2L) treatment with Tivozanib (Tivo) as monotherapy or with Nivolumab (Nivo) in patients (pts) with metastatic renal cell carcinoma (mRCC) previously treated with an immune checkpoint inhibitor (ICI) combination of ipilimumab (Ipi)/Nivo or vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI)/ICI in the Phase 3 TiNivo-2 study
Efficacy of second line (2L) treatment with Tivozanib (Tivo) as monotherapy or with Nivolumab (Nivo) in patients (pts) with metastatic renal cell carcinoma (mRCC) previously treated with an immune checkpoint inhibitor (ICI) combination of ipilimumab (Ipi)/Nivo or vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI)/ICI in the Phase 3 TiNivo-2 study
A Phase 1b Dose Escalation Study of AV-380 (Anti-GDF15 Monoclonal Antibody) in Combination with Standard-of-Care Therapy in Cancer Patients with Cachexia
A Phase 1b Dose Escalation Study of AV-380 (Anti-GDF15 Monoclonal Antibody) in Combination with Standard-of-Care Therapy in Cancer Patients with Cachexia
Integrated Efficacy and Safety Exposure Response (ER) Analysis of Tivozanib (Tivo) for the Treatment of Renal Cell Carcinoma (RCC)
Integrated Efficacy and Safety Exposure Response (ER) Analysis of Tivozanib (Tivo) for the Treatment of Renal Cell Carcinoma (RCC)
Patient-Reported Outcomes (PROs) for Tivozanib + Nivolumab (Tivo-Nivo) vs. Tivozanib (Tivo) Monotherapy in Patients With Renal Cell Carcinoma (RCC) Following an Immune Checkpoint Inhibitor (ICI): Results of the Phase 3 TiNivo-2 Study
Patient-Reported Outcomes (PROs) for Tivozanib + Nivolumab (Tivo-Nivo) vs. Tivozanib (Tivo) Monotherapy in Patients With Renal Cell Carcinoma (RCC) Following an Immune Checkpoint Inhibitor (ICI): Results of the Phase 3 TiNivo-2 Study
ESMO 2024: Tivozanib Plus Nivolumab vs Tivozanib Monotherapy in Patients With Metastatic Renal Cell Carcinoma Following an Immune Checkpoint Inhibitor: Results of the Phase 3 TiNivo-2 Study
ESMO 2024: Tivozanib Plus Nivolumab vs Tivozanib Monotherapy in Patients With Metastatic Renal Cell Carcinoma Following an Immune Checkpoint Inhibitor: Results of the Phase 3 TiNivo-2 Study
SITC 2023: FIERCE-HN: A multicenter, randomized, placebo-controlled, phase 3 study of ficlatuzumab + cetuximab in pts w/ recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC)
SITC 2023: FIERCE-HN: A multicenter, randomized, placebo-controlled, phase 3 study of ficlatuzumab + cetuximab in pts w/ recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC)
CCS 2023: A phase 1b dose escalation study of AV-380 in combination with standard of care chemotherapy in metastatic cancer patients with cachexia and elevated GDF-15 levels
CCS 2023: A phase 1b dose escalation study of AV-380 in combination with standard of care chemotherapy in metastatic cancer patients with cachexia and elevated GDF-15 levels